Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ontario Clinical Oncology Group (OCOG)
With
Ontario Ministry of Health and Long Term Care
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histological or cytological evidence of NSCLC. Must have documented pathology report with histology indicated (e.g. squamous, adenocarcinoma, large cell, NSCLC not otherwise specified).
Stage III (mediastinal node positive) NSCLC based on conventional staging (e.g. computed tomography \[CT\] scan of chest and upper abdomen, CT or magnetic resonance imaging \[MRI\] of brain, bone scan).
Suitable for combined modality (chemotherapy and radiation) therapy or radical radiation therapy or trimodality therapy (chemotherapy, radiation and surgery).
You may not be if
Stage IV NSCLC (by conventional staging).
Small cell lung cancer.
Poor performance status Eastern Cooperative Oncology Group (ECOG) 3-4.
Poor pulmonary function precluding radical radiation therapy (Adequate pulmonary reserve for radical radiation therapy. Pulmonary function tests should have forced expiratory volume in 1 second (FEV1) \> 1.0 liter or \> 40% predicted, diffusing capacity of the lung for carbon monoxide (DLCO) \> 45% and/or predicted contralateral FEV1 \> 800 cc based on quantitative ventilation perfusion lung scan).
Significant concurrent medical problems (e.g. uncontrolled diabetes, active cardiac problems, significant chronic obstructive pulmonary disease).
Insulin dependent diabetic where requirements for PET imaging may be problematic.
Unable to lie supine for at least 30 minutes in radiation treatment position for imaging with PET.
Failure to provide informed consent.
Previous PET scan relating to recent cancer diagnosis prior to entry into study.
Pregnant or lactating females.
Prior thoracic radiation.
Prior malignancy within 3 years from randomization (except nonmelanotic skin cancer or carcinoma in situ of the cervix).
Administered more than two cycles of chemotherapy prior to radical radiation therapy or concurrent chemoradiation (as part of induction or sequential chemotherapy prior to randomization) for the current malignancy.
